The summit commenced with a welcome address by Rajesh Khubchandani, Co-Founder & Managing Director, Team Marksmen Network, who emphasized, “As we start this journey, we have seen a lot of narratives and stories being told. The way a select few organi
Odisha has declared a policy on drugs and medical equipment to bring investments of 25000 crore by 2030. The policy reflects the desire of the state in turning into a large life-sciences hub in eastern India. It was unveiled during the Odisha...
Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals, has signed an exclusive licensing and distribution agreement with Jiangsu Hansoh Pharmaceutical Group. The agreement is for Aumolertinib, a third-generation...
Biocon launches its GLP-1 drug Liraglutide in the Netherlands, entering Europe with branded diabetes and obesity therapies, strengthening its GLP-1 and biologics portfolio.
.png)
Lupin Manufacturing Solutions (LMS), a subsidiary of Lupin Limited, announced a major strategic alliance today with PolyPeptide Group AG, marking a significant move in the expanding peptide market. The long-term partnership aims to build...
Glenmark Pharmaceuticals announced today that its U.S. subsidiary will roll out Leucovorin Calcium for Injection USP, 350 mg/vial in December 2025. The drug is a single-dose vial and is both bioequivalent and therapeutically equivalent to...
Cipla Limited has introduced Yurpeak (tirzepatide) in India, a once?weekly injectable therapy aimed at managing obesity and type?2 diabetes mellitus. After approval by DCGI, the company will market and sell Yurpeak the second brand of tirzepatide...
Pharmaceutical giant Eli Lilly is committing over $6 billion to build an advanced manufacturing plant in Huntsville, Alabama — a major push to bolster U.S.-based drug production. The new facility will focus on making active pharmaceutical...
Viatris is set to sell its stake in Biocon Biologics, a move that could reshape its position in the global pharmaceutical market. Under the definitive agreement, Viatris will transfer its entire convertible preferred equity in Biocon Biologics...
Global pharma leader Lupin has taken a major step forward in the U.S. biosimilar market with a new exclusive licensing agreement for Armlupeg (pegfilgrastim-unne). The company announced today that it has partnered with Valorum Biologics, a...
.jpg)
.jpg)
, CDSCO.jpg)